Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Allogeneic HSCT in patients with MDS or AML 70 years or older has a 3-year overall survival rate of 34%. Good performance status and CMV negativity of the patient result in improved outcome. The number of transplantations in this age group increases rapidly.
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.